# Genetic screening and risk prediction

[Home](../README.md) · [Topic library](../WATCHLIST.md) · [Calendar](../MILESTONES.md)

**Browse:** [Screening and earlier detection](../BROWSE.md#screening).

## Current state

A small matched study associates genotype-guided chemotherapy dosing with fewer severe toxicities. MLD newborn screening connects diagnosis to early care in a small follow-up cohort; MECP2 findings emphasize penetrance and counseling uncertainty. Broad PRS and embryo-selection outcomes remain unproven.

Status: active. **Selective baseline checked September 13, 2026.** Genetics already guides care for some inherited disorders and drug–gene interactions. Broader chronic-disease prediction, population sequencing and polygenic embryo selection have different evidence bases. Better prediction is not automatically better health.

## Questions to follow

- **Inherited disease:** Who benefits from screening for actionable pathogenic variants before symptoms? Does testing relatives lead to earlier treatment and fewer events?
- **Chronic disease:** Do polygenic risk scores improve decisions and outcomes beyond clinical risk factors for cardiovascular disease, diabetes, cancers and other common disorders? Are absolute risks calibrated across ancestries, ages and care settings?
- **Reproduction:** Keep carrier screening, PGT-M, PGT-SR, PGT-A and PGT-P separate. Track live birth, diagnostic error, childhood follow-up and long-term disease outcomes, not only embryo scores or simulated risk reductions.
- **Medication selection:** Which gene–drug pairs improve safety or efficacy when used prospectively? Does a broad commercial panel outperform validated individual recommendations?
- **Newborn screening:** Does sequencing detect treatable disease earlier, with acceptable false positives, missed diagnoses, cost and family burden?
- **Implementation:** Follow counseling, access, variant reclassification, informed consent and useful reanalysis. A variant of uncertain significance is not a diagnosis. Genomic screening of inherited DNA is distinct from tumor-DNA screening and tumor profiling to choose cancer treatment.

## Programs and next milestones

### Focused update — 2026-10-16

<span class="note-anchor" id="note-2026-10-15-elisabeth-hboc-decision-support"></span>

#### ELISABETH registers an EHR-based hereditary-cancer testing pilot

**Development stage:** ELISABETH (NCT07876349), Columbia University, first posted October 15, lists recruiting and an actual September 1, 2026 start. This initial single-group, open-label pilot plans 55 women aged 21–75 with elevated family-history scores, no personal breast/ovarian cancer and no previous germline HBOC testing. It uses EHR-linked clinician support and the RealRisks patient tool.

**Evidence and limitations:** The primary endpoint is change in genetic-testing knowledge at one month. Secondary measures include decisional conflict, understanding of results, reported risk-management decisions and family communication. These are implementation/decision outcomes, not proof that the tool reduces cancer incidence or mortality. Although the title uses “pragmatic trial,” this registered pilot does not have a randomized comparison.

**U.S. status:** Recruiting research at selected NewYork-Presbyterian primary-care clinics; this is not new assay approval or population-wide screening eligibility.

**Next milestone:** Primary and final completion February 28, 2028, both registry estimates.

**Sources:** [Source 1](https://clinicaltrials.gov/study/NCT07876349).

**Remaining gaps:** Focused implementation/discovery update after reading the current genetics page/state. Saved registries and all five hits from the narrow new-registration query were retrieved; ELISABETH was discovered through the overlapping cancer-screening query. Generation Study, WISDOM, international guidance, complete PGT-A/PGT-P literature, ancestry calibration and every pharmacogenomics utility study were not fully refreshed. Recent glossary page update dates were not counted as new evidence. No full successful-check advancement. PATHS-T1D (NCT07802496) still lists not yet recruiting after its October 15 estimated start; Nucleus PGT-P (NCT07841769) likewise remains not yet recruiting after October 1. No actual initiation is inferred from either elapsed estimate.

**Informal-source coverage:** Revisited indexed original September 27 Vitruvian Reddit discussion and current commercial-model context. The saved 14-point IQ claim still does not establish observed selected-offspring benefit; no meaningful status change was found in this bounded search. Original X remained an access gap from prior review; this run did not obtain it. No repeated rumor alert.

[Full coverage record](../updates/2026-10-16_scheduled_research_update.md).


### Focused update — 2026-10-13

<span class="note-anchor" id="note-2026-10-12-dpyd-ugt1a1"></span>

#### Genotype-guided chemotherapy dosing is associated with less severe toxicity

**Publication:** October 12, 2026. A single-center retrospective matched study includes **16 actionable DPYD/UGT1A1 variant carriers given genotype-guided chemotherapy doses versus 75 carriers given standard doses** during 2014–2024. Twelve guided patients received fluoropyrimidines and four irinotecan.

Drug-attributed **grade 3-or-higher or serious toxicity during the first three cycles** occurred in **2/16 (12.5%) versus 38/75 (50.7%)**, matched-design **OR 0.15 (95% CI 0.03–0.68)**. Six guided patients tolerated subsequent dose escalation.

**Limits:** Nonrandom selection, unblinded retrospective attribution, temporal/supportive-care confounding and a small cohort limit causal certainty; the irinotecan subgroup is particularly small. Not all actionable variants were tested. The study did not assess cancer control or survival. Its abstract and results differ on secondary treatment-modification figures, so those are not used here. Safer initial dosing must remain distinct from adequately effective ongoing therapy.

**U.S./next:** This supplements existing drug–gene guidance; publication is not a new testing mandate or coverage decision. Larger clinical implementation and cancer-outcome analyses are needed; date unknown.

**Sources:** [Source 1](https://www.nature.com/articles/s41397-026-00432-2).

<span class="note-anchor" id="note-2026-10-04-mld"></span>

#### MLD newborn screening connects diagnosis to treatment and early development

**Publication:** October 4, 2026. German/Austrian pilots screened **359,282 newborns** during September 2021–July 2025 using sulfatides, ARSA enzyme activity and genetic sequencing. **Nine screen-positive infants had confirmed MLD**; no known false negative or false positive was reported.

Seven were referred for early-onset gene therapy, but the **full text reports only five actually treated**, one awaiting infusion and one in preparation at the December 2025 data cutoff. After 6.3–30.2 months(median 18.5), four of five had age-appropriate development; one had mild motor delay. Peripheral neuropathy continued in some children. Two predicted late-onset cases remained under surveillance.

**Safety/limits:** Three catheter-associated adverse events resolved; no gene-product-related serious event was reported. Small uncontrolled numbers and short follow-up do not prove lifelong protection or zero missed cases. The combined biochemical/genetic pathway is not broad genome-only screening. Screening detected actionable disease and changed management, beyond variant yield, but long-term outcomes remain incomplete.

**U.S./next:** No new U.S. authorization from this paper. Longer developmental, neuropathy, transplant-safety and implementation follow-up is needed; date unannounced.

**Sources:** [Source 1](https://link.springer.com/article/10.1186/s13023-026-04620-y).

<span class="note-anchor" id="note-2026-10-05-earlycheck-mecp2"></span>

#### Newborn MECP2 findings highlight uncertain penetrance and family counseling

**Source:** October 5, 2026 online journal pre-proof in Genetics in Medicine Open. Early Check's North Carolina genomic newborn program screened approximately 200 genes using residual dried blood spots.

Among **5,143 newborns**, **three had pathogenic MECP2 variants**, followed by confirmatory and family testing. Testing also identified two previously unrecognized adult female carriers and a reported paternal transmission. These findings prompt questions about penetrance, inheritance and counseling in a population-screened setting.

**Limits:** Only three infant findings; this does not establish a precise population prevalence, universal Rett-syndrome prediction, or improved health from adding MECP2 to all screening panels. Variant classification, age/sex-dependent expression and longitudinal phenotype are separate from sequence detection. The primary abstract/pre-proof metadata were appraised; full case details and follow-up remain inaccessible.

**U.S./next:** Research detection is not a new national screening requirement or routine coverage decision. Longitudinal infant/family outcomes and penetrance clarification remain needed, with no announced date.

**Sources:** [Source 1](https://www.sciencedirect.com/science/article/pii/S2949774426010113).

**Remaining gaps:** Read broad genetics scope/state and September 6 overlap; all 7 saved registries plus 5 new registrations retrieved. Appraised full Oct 12 DPYD/UGT1A1 toxicity and Oct 4 MLD newborn implementation papers; Oct 5 MECP2 pre-proof primary abstract retrieved but full article inaccessible.; PGTP NCT07841769 remains not-yet-recruiting in Sept 25 record despite elapsed Oct 1 estimate. MGB T1D genetic-risk study retains Oct 15 estimatedstart, not actual initiation. FOCUS Sept 8 record still has 8 enrollment versus 12 test-site narrative mismatch; not promoted to resolved baseline.; All PGT-M/SR/A guidance, carrier/cascade testing, multiancestry PRS intervention trials and newborn sequencing programs not comprehensively refreshed. MECP2 full infant outcomes and cancer-germline Oct 8 supplements remain gaps.

**Informal-source coverage:** Revisited original indexed Nucleus/Vitruvian source chain and matched live PGT-P registry: no clinical offspring-outcome confirmation or verified actual start; prior model 14.3 highest-to-lowest remains separate from top-versus-average gain. Newborn blog/case reports are not controlled outcomes. Full commercial/podcast transcript review incomplete.

[Full coverage record](../updates/2026-10-13_scheduled_research_update.md).


### Focused update — 2026-10-09

#### Large cancer cohort finds inherited variants beyond early-onset cases

**Source/event date:** October 8, 2026 publication. **Evidence:** Cancer Discovery observational cohort; AACR and investigator reporting appraised. Full article and supplements remain inaccessible.

Germline sequencing in **39,184 patients with 32 solid-tumor types** interrogated more than 90 cancer-predisposition genes without selecting only clinically suspected hereditary cases. Pathogenic variants occurred in **16.3%** overall; prevalence was **18.4%, 15.6%, and 12.3%** in tumor-specific early-, average-, and late-onset groups. A simple restriction to diagnosis before age 50 would miss **4,601 carriers, 72%** of the identified carriers.

**Limits:** This is a single tertiary-center cancer cohort, predominantly European/Ashkenazi ancestry, not healthy-population screening or a polygenic-score trial. Actual guidelines use more than age alone. Variant yield and potential actionability do not themselves show improved survival, successful cascade testing, or benefit from testing every person.

**U.S. status / next milestone:** Publication is not a new guideline, coverage mandate, or test approval. Follow prospective changes in management, cascade-testing uptake, and clinical outcomes; timing unknown.

[AACR study report](https://www.aacr.org/about-the-aacr/newsroom/news-releases/current-age-based-genetic-testing-in-patients-with-cancer-may-miss-majority-of-inherited-gene-variants/); [primary paper](https://doi.org/10.1158/2159-8290.CD-26-0971).

**Sources:** [Primary source 1](https://www.mskcc.org/news/study-suggests-every-cancer-patient-should-be-tested-for-inherited-cancer-mutations).

<span class="note-anchor" id="yale-plans-a-5-000-person-primary-care-genomic-screening-pilot"></span>

#### Yale plans a 5,000-person primary-care genomic-screening pilot

**Source/event date:** October 6, 2026 announcement. **Evidence:** Official Yale description of planned human research in the NIH Population Genomic Screening Network.

Yale plans to enroll **5,000 patients**, following each for **at least 24 months**, across academic, private-primary-care, community-hospital, and community-health-center settings. The condition list is not final; hereditary breast/ovarian cancer, Lynch syndrome, familial hypercholesterolemia and other actionable inherited conditions are proposed. Workflows cover consent, sampling, return of results, referral and follow-up.

**Limits:** This is an implementation plan, not a reported improvement in health. Identification of a variant must be distinguished from changed management, patient outcomes, costs and harms. Actual recruitment, a matched registry, and the final protocol were not verified.

**U.S. status / next milestone:** Research infrastructure is not universal coverage or a general screening recommendation. Verify initiation and the condition list; no announced results date. The five-year award and 24-month individual follow-up do not justify inventing a readout date.

[Official Yale announcement](https://medicine.yale.edu/news-article/yale-pilots-genomic-screening-through-primary-care/).

**Sources:** [Primary source 1](https://popgenscreening.org/).

**Remaining gaps:** Read current topic/state and September6 overlap. All seven saved registries and new-registration discovery retrieved. PGT-P NCT07841769 remains not yet recruiting in Sept25 record after its Oct1 estimated start; actual start unverified.; Appraised official Oct8 AACR/MSK germline-study reports and Oct6 Yale planned prospective project. Primary germline full paper failed403; PubMed unavailable and EuropePMC not yet indexed. Do not claim full paper/supplement appraisal.; PGT-M/SR/A guidance, newborn genomic screening and pharmacogenomics were not comprehensively refreshed. New FOCUS Sept8 population-genomic implementation registry was located, but inconsistent site/sample counts require detailed follow-up before promoting it.

**Informal-source coverage:** Revisited original Nucleus/Vitruvian source chain and sponsor September whitepaper. Five-embryo top-versus-bottom10.8IQ and ten-embryo14.3IQ are model projections with predominantly European-ancestry sibling validation; not observed offspring outcomes or top-versus-average gain. Original X remains inaccessible. No new confirmation/retraction found; leave existing rumor unconfirmed without repeat alert.

[Full coverage record](../updates/2026-10-09_scheduled_research_update.md).


### Focused update — 2026-10-06

<span class="note-anchor" id="genome-sequencing-increases-diagnostic-yield-in-a-developmental-disorder-trial"></span>

#### Genome sequencing increases diagnostic yield in a developmental-disorder trial, with an adjusted uncertainty

**Source/event date:** October 5, 2026 publication. **Evidence:** Peer-reviewed BeSolveRD randomized diagnostic-strategy trial; **NCT07051213**, registered retrospectively.

Across eight Belgian genetics centers, **567 people with unexplained developmental disorders/intellectual disability/congenital anomalies** received genome sequencing or standard exome plus chromosomal-microarray/shallow-genome testing. Diagnostic yield was **113/284 (39.8%) versus 85/283 (30.0%), p=.015**. After adjustment for sex and analytical differences, the estimated advantage fell to **7.3 percentage points, p=.069**. The study recruited June 2021–July 2024 and stopped below its planned 800; October 2026 is publication, not trial initiation.

**Limits:** Phenotype-selected diagnostic patients and mainly trio sequencing; these findings do not show benefit of sequencing all healthy people, PRS-guided prevention or polygenic embryo selection. Diagnostic yield is distinct from demonstrated improvement in treatment, function, survival or cost-effectiveness. Illumina provided sequencing consumables/platform access. Safety outcomes and longitudinal management benefit were not established.

**U.S. status / next milestone:** No new U.S. approval or guideline change from this paper. Replication and prospective management/outcome evidence remain needed; no announced next date.

[Full primary paper](https://link.springer.com/article/10.1186/s13073-026-01771-2).

#### Recovered Nucleus whitepaper clarifies modeled embryo-score spreads

**Source date:** September 2026, exact publication day not established; reviewed October 6. **Evidence:** Recovered sponsor modeling whitepaper; **baseline addition, not a new October result**.

Nucleus evaluated trait scores in approximately **40,000 siblings/20,000 sibling pairs of European ancestry in UK Biobank**, excluding validation individuals/close relatives from model development. Intelligence training used approximately 500,000 people; sponsor-reported within-family R² was **.191** on a reliability-adjusted latent cognitive scale. Table 2 estimates a highest-to-lowest IQ spread of **10.8 points among 5 embryos** and **14.3 among 10**. The paper explicitly says expected top-versus-average gain is **half the spread**.

**Limits:** Adult sibling-score validation and computational selection projections are not observed IQ or health outcomes in selected children. European-ancestry validation, available viable embryos, assay/reliability assumptions and individual variation constrain use. Selection does not edit DNA.

**Rumor follow-up:** Existing September 27 Reddit quotation links [Kian Sadeghi’s original X permalink](https://x.com/KianSadeghi5/status/2101018839412531231), which returned 403. The numerical model context is now accessible; original wording and the generic 14 point-benefit claim remain unconfirmed. No marketing-authorization or professional-guidance change is established.

[September whitepaper](https://mynucleus.com/labs/traits-whitepaper); [existing Reddit source](https://www.reddit.com/r/singularity/comments/1wrq633/introducing_vitruvian_a_genetic_optimization/).

**Coverage:** genomic screening polygenic risk pharmacogenomics newborn embryo October 2026 clinical trial; genetic screening embryo polygenic October 2026 trial Nucleus after:2026-09-25 before:2026-10-07; "genetic" "September 2026" "October 2026" "clinical utility" newborn polygenic trial; site:reddit.com genetic screening embryo polygenic Nucleus October 2026; site:reddit.com Nucleus Vitruvian 14 IQ September October 2026

**Remaining gaps:** Read current genetics/PGT-P notes and state. October5 BeSolveRD primary full paper appraised. Reopened Nucleus official Labs and newly found original September whitepaper.; Recovered direct social permalink through existing Reddit post; X403, original post not independently verified. Whitepaper closes important model-method and ancestry gaps without establishing observed offspring benefit.; Live Nucleus NCT07841769 and T1D NCT07802496 APIs inaccessible; elapsed estimated start not verified. Full newborn/carrier/cascade/PGx inventory incomplete; whitepaper is recovered baseline, not newOctober6 model launch.

**Informal-source coverage:** Original September27 Reddit reproducing Kian Sadeghi/Nucleus claim revisited; direct X permalink recovered but403. Sponsor whitepaper gives14.3-point modeled highest-lowest spread with10 European-ancestry embryos, top-vs-average gain half that, not generic14point observed gain. Existing stable key nucleus_vitruvian_2026-09-27_IQ_claim remains unconfirmed as worded; sources/methods clarified, no repeated alert or offspring benefit claim.

[Full coverage record](../updates/2026-10-06_scheduled_research_update.md).


### Focused update — 2026-10-02

No additional material finding was verified in this focused pass. Coverage remains incomplete; this is not a full-topic “no news” conclusion.

**Coverage:** genomic newborn screening polygenic risk clinical utility pharmacogenomics September 29 October 1 2026; genetic embryo selection Nucleus Vitruvian 14 IQ points September 2026 original source; ClinicalTrials.gov NCT07841769 NCT07802496 October 2026 recruitment; site:reddit.com genetics Generation Study September 2026 results embryo selection.

**Remaining gaps:** Full prospective clinical-utility and cascade-testing inventory, pharmacogenomic trials and professional guidance were not exhaustively refreshed. Nucleus whitepaper/full ancestry calibration and original social post behind the 14-point claim were not obtained. BEACONS-NBS condition-selection preprint identified but full methods not appraised; no prospective benefit claim made.

**Informal-source coverage:** Nucleus/Vitruvian 14-IQ-point embryo-selection claim; https://www.reddit.com/r/singularity/comments/1wrq633/introducing_vitruvian_a_genetic_optimization/; Still secondhand and unconfirmed. Official Labs page rechecked October2 still describes approximately 10.8 points as modeled highest-to-lowest spread among five embryos; this is not average gain over random selection, not an observed offspring result and does not corroborate the separate 14-point framing. No new rumor alert. https://www.reddit.com/r/BeyondTheBumpUK/comments/1wpsxs1/the_generation_study_we_heard_back_and_its_not/; September25 individual newborn-screening result discussion is a personal account, not new cohort clinical-utility evidence.

**Next update:** Nucleus study estimated start October 1, 2026 and completion September 30, 2029; PATHS-T1D estimated start October 15, 2026. Neither supplies long-term embryo-selection benefit data.

[Full coverage record](../updates/2026-10-02_scheduled_research_update.md).

### Focused update — 2026-09-29

#### New polygenic embryo-selection study will measure early pregnancy success

**Source date:** 2026-09-25. **Evidence:** Trial-registry announcement.

Nucleus registered NCT07841769, a prospective observational comparison of patients choosing polygenic-score-based versus morphology-based embryo selection. It is not yet recruiting, with about 2,000 participants planned. The registered primary endpoint is ongoing pregnancy per transfer at discharge from IVF care, 8–12 weeks. A secondary endpoint compares disease-risk scores with embryo morphology.

**Limitations:** Families choose their selection strategy; there is no random allocation. This cannot establish long-term offspring disease prevention, intelligence gains, or general clinical utility. Ancestry calibration, available embryo numbers and self-selection remain important limitations. Registry narrative claims about adult/sibling data are not offspring outcomes.

**Safety:** No results or prospective safety outcomes are available.

**U.S. status:** Research registration is not FDA approval, professional endorsement or validation of a commercially offered test.

**Next milestone:** Estimated start October 1, 2026; estimated primary/final completion September 30, 2029. Neither is a guaranteed readout date.

[Original trial registry](https://clinicaltrials.gov/study/NCT07841769).

**Coverage:** September 6–29 discovery covering PRS, inherited screening, newborn sequencing, pharmacogenomics and reproductive testing. Verified Nucleus new registry and unchanged PATHS-T1D; reviewed commercial-model/social claim distinction.

**Remaining gaps:** Full Nucleus protocol/statistical plan and whitepaper were not appraised; no prospective offspring outcome verified. Newborn September28 JAMA item is a perspective, not a new outcome study. International prospective-utility and ancestry-calibration census incomplete.

**Informal-source coverage:** September27 Reddit Vitruvian claim is saved separately as unconfirmed interpretation. Primary company page describes modeled highest-to-lowest score spreads, not observed child outcomes; original social announcement was not located.

**Next update:** Nucleus study estimated start October 1, 2026 and completion September 30, 2029; PATHS-T1D estimated start October 15, 2026. Neither supplies long-term embryo-selection benefit data.

[Full coverage record](../updates/2026-09-29_scheduled_research_update.md).

### Focused update — 2026-09-27

#### Short pharmacogenomic hypertension trial reports better blood-pressure control, with major design limits

**Source date:** 2026-09-18. **Event date:** 2026-09-18. **Evidence:** Peer-reviewed open-label randomized trial.

A 14-hospital Chinese trial randomized 2,702 adults to seven-locus pharmacogenomic guidance or usual treatment for four weeks. BP <140/90 was reported in 1,177/1,351 (87.1%) versus 297/1,351 (21.9%). Median systolic changes were −27 (IQR −36 to −18) versus −10 (−19 to −3) mmHg; these are medians/IQRs, not means/CIs.

**Limitations:** Unblinded care and assessment, baseline medication imbalance and more frequent treatment changes/intensification complicate attribution to genetic matching. Short follow-up, selected Han Chinese population and no clinical cardiovascular outcomes limit applicability; no trial registration was located in the paper.

**Safety:** Four adverse events in the guided group versus none in control; no serious events over four weeks. This does not support a claim of fewer adverse reactions.

**U.S. status:** No U.S. screening recommendation, approved universal panel or proven event-prevention benefit follows.

**Next milestone:** Independent longer-term validation with balanced management intensity and clinical outcomes; date unknown.

[Primary pharmacogenomic hypertension trial](https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2026.1842597/full).

**Coverage:** September 6–27 genetic-screening discovery: full pharmacogenomic hypertension paper, chronic-disease risk, newborn sequencing, reproductive testing and PRS discussions. Deduplicated prior PGT-A and genetic-enrichment findings.

**Remaining gaps:** Full prospective utility/ancestry-calibration census incomplete; commercial embryo-score whitepaper and current professional-guidance/advertising decisions not fully appraised. No measured long-term polygenic-embryo offspring outcome verified.

**Informal-source coverage:** September 23 Reddit newborn-genomics review discussion repeats prior studies; no new prospective clinical-outcome rumor verified. Commercial embryo models were not converted into offspring outcomes. https://www.reddit.com/r/heredity/comments/1wofudt/international_experiences_of_genomic_newborn/

**Next update:** Genetic-risk-guided T1D study start estimated October 15, 2026. Independent PGx validation, ancestry-calibrated clinical utility and long-term embryo-selection outcomes remain undated.

[Full coverage record](../updates/2026-09-27_scheduled_research_update.md).

### Focused update — 2026-09-22

#### Baseline addition: genetic-risk-guided type 1 diabetes screening study

**Source date:** 2026-09-03. **Event date:** 2026-09-03. **Evidence:** Trial-registry baseline; last updated September 8.

A planned MGB Biobank study will test whether genetic enrichment helps identify presymptomatic type 1 diabetes. This is an older registration newly added to the watch, not a September 22 launch. NCT07802496 targets about 150 adults aged 18–79, initially selected from the top 2.5% of a T1D polygenic score. Researchers will examine islet autoantibodies, clinical features and added discrimination; ancestry covariates are included.

**Limitations:** Not yet recruiting, no results. Enrichment and discrimination do not establish prevention benefit, general-population calibration or utility across ancestries; research findings may require clinical laboratory confirmation.

**Safety:** Observational testing protocol, not a therapeutic safety study.

**U.S. status:** Research-only protocol; no new commercial screening recommendation.

**Next milestone:** Estimated start October 15, 2026; primary completion October 2029. Registry estimates are not readout promises.

[Original registry](https://clinicaltrials.gov/study/NCT07802496).

#### Recovered baseline: biopsy PGT-A cohort separates whole-chromosome from segmental aneuploid transfer outcomes

**Source date:** 2026-09-01. **Event date:** 2026-09-01. **Evidence:** Recovered baseline; peer-reviewed retrospective multicenter cohort; original abstract appraised.

No live births in 168 WCA transfers; 17.1% live birth after 82 SA transfers. This supports treating these classifications separately, not applying a single prognosis to every aneuploid result. WCA outcomes: 78.6% no pregnancy, 8.3% biochemical pregnancy, 1.8% ectopic, 9.5% early spontaneous abortion, 1.2% late spontaneous abortion, 0.6% therapeutic termination. Neonatal gestation/birthweight available for 10 SA live births did not differ from same-center euploid-transfer births; all genetically tested cases were normal, but abstract does not state how many underwent genetic testing.

**Study population:** 250 transfers with complete clinical outcomes during 2016–2026 from 8 of 26 IRMET centers: 168 non-mosaic whole-chromosome aneuploid (WCA), 82 segmental aneuploid (SA). Trophectoderm biopsy plus WGA/NGS. 111 WCA transfers occurred without knowledge of the PGT-A classification.

**Limitations:** Retrospective, selected transfers with complete records; no random allocation to PGT-A vs no testing; ages, adjusted comparisons, assay thresholds, segment-size details and full clinical follow-up unavailable in abstract. Does not establish cumulative live-birth benefit of routine PGT-A, universal impossibility of birth after WCA classification, or embryo-wide karyotype from a biopsy. Neither mosaic-transfer evidence nor PGT-P/polygenic selection research.

**Safety:** WCA pregnancies included ectopic pregnancies, losses and termination. Only 10 SA neonatal records described; normal tested results and similar birthweight do not establish long-term offspring safety.

**U.S. status:** No new authorization or professional-guideline change from this paper; not an individual embryo-transfer recommendation.

**Next milestone:** Independent prospective validation and longer offspring follow-up; no announced date.

[Original indexed research abstract](https://pubmed.ncbi.nlm.nih.gov/42679947/); [Original Fertility and Sterility DOI](https://doi.org/10.1016/j.fertnstert.2026.08.1124); [Original abstract and electronic-publication metadata via Europe PMC](https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:42679947&format=json&resultType=core).

**Related findings:**

- [p-tau217 plus APOE refines cognitive-risk estimates in pooled cohorts](08_alzheimers.md#programs-and-next-milestones).

**Coverage:** Verified new-to-watch T1D polygenic-risk screening registration; searched PRS/PGT/newborn/PGx research and deduplicated September 8 non-invasive PGT-A trial.

**Remaining gaps:** Full SPLENDID/newborn/PGx/cascade-testing inventory remains partial. The PGT-A cohort abstract was appraised; full-paper methods, adjusted comparisons and long-term offspring follow-up remain unreviewed. No generic embryo-safety claim is inferred.

**Informal-source coverage:** September 18 IVF discussion linked primary PGT-A research; avoid adopting commenters’ generalized efficacy claims or treating clinic anecdotes as trials. https://www.reddit.com/r/IVF/comments/1wk6bz5/new_study_17_lbr_for_segmental_aneuploid_embryos/

[Full coverage record](../updates/2026-09-22_scheduled_research_update.md).

**Next update:** T1D PRS screening start estimated **October 15, 2026**, primary completion **October 2029**. Clinical utility and long-term embryo-selection outcomes remain undated.

### Focused update — 2026-09-18

#### Non-invasive embryo chromosome screening does not improve the primary pregnancy outcome

**Source date:** 2026-09-08. **Evidence:** Peer-reviewed randomized trial; accepted early article.

A large randomized trial found no significant improvement in ongoing pregnancy or live birth after the first transfer with non-invasive PGT-A versus morphology-based selection. NCT04339166 enrolled women aged 35–42 with at least two blastocysts at 13 Chinese centers. The modified intention-to-treat analysis included 1,152 couples: ongoing pregnancy beyond 12 weeks was 38.7% (221/571) versus 36.8% (214/581), adjusted p=.49; live birth was 37.0% versus 35.5%, p=.59. Early miscarriage was lower in a secondary analysis.

**Limitations:** This tests cell-free DNA from embryo culture medium, not embryo-biopsy PGT-A or polygenic PGT-P. First-transfer success is not cumulative live birth per retrieval. The abstract lists 1,189 allocated and 1,152 analyzed; these denominators are kept distinct.

**Safety:** No serious adverse events reported; maternal/neonatal differences were not significant. Long-term offspring outcomes were not established.

**U.S. status:** Research result, not a new U.S. authorization or proof of routine clinical utility.

**Next milestone:** Final publication and further clinical-utility evidence; no dependable next date.

[Original trial, September 8](https://www.nature.com/articles/s41467-026-77628-4); [Trial registry](https://clinicaltrials.gov/study/NCT04339166).

#### SPLENDID improves cross-ancestry polygenic prediction in biobank analyses

**Source date:** 2026-09-14. **Evidence:** Peer-reviewed human-genetic methods study.

SPLENDID models ancestry as a continuum and improves prediction in diverse biobank populations; clinical benefit from using it has not been tested. The study combined simulations with All of Us (224,364 people) and UK Biobank (340,140). It reports improved prediction, particularly for non-European and admixed ancestries, without requiring discrete ancestry labels.

**Limitations:** This is prediction/model validation, not a randomized test of risk-guided prevention, and not validation of embryo ranking or long-term offspring benefit. The original abstract was retrieved through Europe PMC; full model-performance tables were not appraised.

**Safety:** Clinical harms and downstream management effects were not evaluated.

**U.S. status:** Publication does not establish a newly approved U.S. screening test.

**Next milestone:** Prospective calibration, implementation and outcome studies; no firm date.

[Nature Methods, September 14](https://www.nature.com/articles/s41592-026-03235-2); [Primary abstract](https://pubmed.ncbi.nlm.nih.gov/42736360/).

#### Advertising review challenges precision claims for embryo selection

**Source date:** 2026-09-11. **Evidence:** Advertising self-regulatory decision; appeal announced.

NAD recommended changing or discontinuing specific Nucleus IVF+ embryo-comparison claims; Nucleus announced an appeal. The decision questioned whether submitted evidence validated ranking a group of sibling embryos and the advertised numerical differences in disease risk, height and IQ, as well as definite eye/hair-color predictions.

**Limitations:** This is an advertising self-regulatory finding, not an FDA ban, a new clinical trial, or a determination that all genetic testing lacks value. Keep it separate from inherited-disease PGT-M and the non-invasive PGT-A trial.

**Safety:** No new clinical safety outcome was measured.

**U.S. status:** Commercial offering and claim substantiation are separate; no change in FDA authorization is established.

**Next milestone:** Appeal outcome; no date announced.

[NAD decision, September 11](https://bbbprograms.org/media/newsroom/decisions/nucleus-genomics).

**Related findings:**

- [Patidegib Gorlin-syndrome study completes follow-up; results forecast for November](14_cancer_vaccines.md#programs-and-next-milestones): The phase 3 SGT-610 study has completed its final patient visit; the sponsor forecasts topline results in late November 2026.

**Coverage:** Original niPGT-A paper and registry, SPLENDID abstract, NAD advertising decision, newborn/PRS/embryo discovery. This is a focused review, not a complete re-review of every program.

**Remaining gaps:** Full SPLENDID tables, Generation follow-up, pharmacogenomic and carrier/cascade studies not comprehensively refreshed.

**Informal-source coverage:** Reddit genetics/PGT discussion largely opinion or old commercial claims; no independently attributable new development rumor selected. Models and embryo-editing laboratory stories not promoted to clinical outcomes.

[Full coverage record](../updates/2026-09-18_scheduled_research_update.md).

### Inherited risk: finding conditions that can change care

Hereditary breast/ovarian cancer, Lynch syndrome and familial hypercholesterolemia illustrate established uses of clinically indicated genetic testing and testing relatives after a familial finding. This does not establish the benefit of sequencing every healthy adult for every disease. The next question is how broader screening changes prevention, diagnoses and outcomes—not simply how many variants it finds. U.S. testing is available for specific clinical purposes; eligibility and follow-up depend on the condition. [CDC genetic counseling overview](https://www.cdc.gov/genomics-and-health/counseling-testing/genetic-counseling.html); [CDC discussion of population screening versus established applications](https://blogs.cdc.gov/genomics/2020/08/11/the-long-road/).

### Chronic-disease prediction: from risk scores to clinical decisions

- **eMERGE:** A March 2026 study reported returning genome-informed risk assessments to **23,840 adults and children**, combining polygenic scores, monogenic variants and family history for 11 conditions. It demonstrates delivery at scale and identifies barriers to returning results. It does **not** demonstrate that the program prevented those diseases. Watch downstream care, outcomes and equitable uptake; no next outcome-publication date was verified. [Primary study](https://pubmed.ncbi.nlm.nih.gov/41875895/).
- **Cardiovascular and metabolic risk:** A 2026 study developed and externally validated integrated scores for eight traits, including coronary disease, type 2 diabetes, severe hypercholesterolemia and elevated Lp(a). It supports risk stratification, while the authors explicitly call for more prospective clinical-utility evidence. A clinically orderable test is not proof that testing reduces heart attacks or replaces measured lipids. [Primary validation study](https://pubmed.ncbi.nlm.nih.gov/42053472/). Cross-link [cardiovascular prevention](07_cardiovascular.md).
- **WISDOM breast screening — NCT02620852:** The randomized study combined genetic and clinical risk to choose screening schedules. Over median follow-up of about five years, risk-based screening met its noninferiority endpoint for stage IIB or higher cancers, but did not significantly reduce biopsy rates. This tests a combined screening strategy, not polygenic scoring alone, and is not proof of lower mortality. WISDOM 2.0 is developing updated ancestry-aware and subtype-specific assessment; no firm next readout date was verified. [Corrected primary trial report, published online December 2025](https://jamanetwork.com/journals/jama/fullarticle/2842903).
- **BARCODE1 prostate screening — NCT03857477:** The April 2025 report used a saliva-derived score to select men aged 55–69 in the highest risk decile for screening. It found clinically significant cancers that standard PSA/MRI pathways would have missed. This was a selected-cohort detection study, not a randomized mortality trial. Watch unnecessary biopsies, overdiagnosis, applicability across ancestries and clinical-outcome studies. [Primary report](https://www.nejm.org/doi/10.1056/NEJMoa2407934). Cross-link [organ-specific cancer screening](02_galleri.md).

**New validation evidence:** September 10 ischemic-stroke PRS research found only small gains beyond clinical covariates and weaker transfer across ancestry groups. See the dated September 14 entry for effect sizes and limits; no clinical-outcome readout or implementation date is established.

### Embryo testing and selection: different tests answer different questions

| Test | What it assesses | What must remain distinct |
| --- | --- | --- |
| Carrier screening | Parental variants associated with inherited conditions | Identifies reproductive risk; it does not select or test an embryo. |
| PGT-M | A specific monogenic condition or familial variant in IVF embryos | Clinical use for appropriate indications; test development, residual error and confirmatory testing matter. |
| PGT-SR | Chromosome imbalances associated with a parental structural rearrangement | Different from a polygenic estimate of future chronic disease. |
| PGT-A | Chromosome copy number | Does not rank common-disease risk; routine use has not shown benefit for every IVF population. |
| PGT-P / polygenic embryo screening | Estimated risk of multifactorial diseases | Research on prediction and selection exists; long-term health improvement in resulting children remains unproven. |

PGT-M is an established clinical option for selected inherited risks, with individualized laboratory work and counseling. PGT-A's value depends on the population and outcome; success per transfer and cumulative live birth per retrieval answer different questions. [ASRM PGT-M guidance](https://www.asrm.org/practice-guidance/practice-committee-documents/indications-and-management-of-preimplantation-genetic-testing-for-monogenic-conditions-a-committee-opinion-2023/); [ASRM PGT-A guidance](https://www.asrm.org/practice-guidance/practice-committee-documents/the-use-of-preimplantation-genetic-testing-for-aneuploidy-a-committee-opinion-2024/).

**PGT-P research is included in this watch.** A January 2026 paper modeled how rare breast-cancer variants and polygenic scores interact in embryo selection. It shows why ignoring either source of risk can distort a ranking; it used simulation and mathematical modeling, not observed cancer outcomes in children selected by these tests. [Primary modeling study](https://www.nature.com/articles/s41525-025-00546-9).

ASRM's 2026 opinion considers PGT-P unproven and recommends research oversight rather than clinical offering. That is professional guidance, not a statement that research or commercial offerings do not exist. Useful future evidence would compare predicted with observed outcomes, account for ancestry and the number of embryos available, and express absolute rather than only relative risk changes. Ranking embryos changes which embryo is transferred; it does not edit DNA. No confirmed date for definitive long-term offspring results was found. [ASRM PGT-P opinion](https://www.asrm.org/practice-guidance/ethics-opinions/use-of-preimplantation-genetic-testing-for-polygenic-disorders-pgt-p-an-ethics-committee-opinion-2026/).

### Pharmacogenomics: selecting drugs and doses

The **PREPARE study — NCT03093818** tested a 12-gene panel with guideline-guided prescribing across seven European countries. Its open-label cluster-randomized implementation study reported fewer clinically relevant adverse drug reactions over 12 weeks. This supports the tested prescribing approach; it does not validate every panel or guarantee the most effective antidepressant for an individual. Most participants reported European, Mediterranean or Middle Eastern ethnicity, limiting generalization. U.S. use is gene–drug specific. Watch replication, broader representation and prospective benefit for particular medicines. [2023 primary report](https://pubmed.ncbi.nlm.nih.gov/36739136/). Cross-link [mental-health treatments](10_ssri_antidepressants.md).

### Newborn genomes: earlier diagnosis of treatable disease

England's **Generation Study** aims to sequence 100,000 newborns for more than 200 rare conditions. Its evaluation asks whether sequencing adds useful diagnoses, improves access to treatment, and is acceptable and cost-effective compared with standard screening. Positive research screens require diagnostic follow-up. It is an England-based research program, not a U.S. universal screening recommendation. [Program overview](https://www.genomicsengland.co.uk/initiatives/newborns); [evaluation questions](https://www.genomicsengland.co.uk/initiatives/newborns/evaluation).

**Next window: summer 2027 for completion of sequencing**, according to a March 16, 2026 UK government answer. Evaluation and consideration by the UK National Screening Committee follow; this is a government forecast for sequencing completion, not a promised publication or implementation date. [Parliamentary answer, page 107](https://qna.files.parliament.uk/qnadailyreports/Written-Questions-Answers-Statements-Daily-Report-Commons-2026-03-16.pdf).

## Rumors and informal signals

<span class="note-anchor" id="note-2026-10-06-nucleus-rumor-context"></span>

### October 6 source-chain follow-up

**Informal claim — unconfirmed.** Original X permalink found but returned 403. Sponsor September whitepaper models highest-to-lowest IQ spread of 14.3 points among ten viable embryos; top-versus-average modeled gain is half. Adult European-ancestry sibling validation is not observed selected-offspring benefit. Methods/provenance gap partly closed; not new October efficacy evidence.

[Source 1](https://x.com/KianSadeghi5/status/2101018839412531231) · [Source 2](https://www.reddit.com/r/singularity/comments/1wrq633/introducing_vitruvian_a_genetic_optimization/) · [Source 3](https://mynucleus.com/labs/traits-whitepaper)

Stable key: `nucleus_vitruvian_2026-09-27_IQ_claim`.


### September 29 informal-source check

<span class="note-anchor" id="note-2026-09-27-informal-claim-unconfirmed-vitruvian-can-increase-a-childs-iq-by-14-points"></span>**Informal claim — unconfirmed: Vitruvian can increase a child’s IQ by 14 points.** A September 27 r/singularity post reproduces an attributed Nucleus announcement claiming a 14-point benefit. The original social post was not located; this is a secondhand quotation, not a verified offspring outcome. The company’s September 2 model page instead describes an expected 10.8-point highest-to-lowest spread among five embryos. A predicted spread is not gain versus an average/randomly selected embryo and is not a guarantee for a child. Full whitepaper and the provenance of the 14-point formulation remain unreviewed. This is selection among existing embryos, not DNA editing. Ancestry, embryo number and validation setting matter.

**Next check:** Seek original announcement and full model methods; watch prospective outcomes separately. No clinical benefit inferred from the new pregnancy study.

[September 27 Reddit source (secondhand)](https://www.reddit.com/r/singularity/comments/1wrq633/introducing_vitruvian_a_genetic_optimization/); [Nucleus model update](https://mynucleus.com/labs).

## Dated history

### 2026-10-02 — Scheduled focused review

0 newly recorded findings or milestones; primary evidence, uncertainty and incomplete coverage are detailed above and in the [run record](../updates/2026-10-02_scheduled_research_update.md). Full-topic successful-check dates remain unchanged.

- **2026-09-29:** 1 sourced entries, 0 cross-topic links and 1 informal-source checks. [Coverage and gaps](../updates/2026-09-29_scheduled_research_update.md).

- **2026-09-27:** 1 sourced entries and 0 cross-topic links from a focused scheduled check. [Coverage and remaining gaps](../updates/2026-09-27_scheduled_research_update.md).

- **2026-09-22:** Focused scheduled research retry; 2 sourced entries and 1 cross-topic links. [Coverage and gaps](../updates/2026-09-22_scheduled_research_update.md).

### 2026-09-14 — Focused ad-hoc update

**Stroke polygenic scores show small, ancestry-dependent gains in external validation.** A multi-cohort study evaluated function-informed and ancestry-specific ischemic-stroke polygenic risk scores. In All of Us participants of European ancestry, the strongest score had an odds ratio of 1.16 per standard deviation (95% CI 1.12–1.19), but adding scores moved discrimination only from about 66.0% to 66.3–66.6%. In the African-ancestry group, performance gains were negligible; the corresponding score association was 0.99 (0.94–1.05). This is model validation, not proof that PRS-guided screening or treatment improves health outcomes. It reinforces the need for ancestry-specific validation and modest expectations for incremental prediction. [Original study, September 10](https://www.frontiersin.org/journals/bioinformatics/articles/10.3389/fbinf.2026.1875388/full).

**Next:** No clinical availability or dated interventional milestone supported.

**Coverage and limitation:** The paper’s abstract and results differ on the REGARDS holdout denominator, so that count is not used here. Recent genomic-screening, newborn, PRS and embryo-screening searches were selective; Generation Study, WISDOM and reproductive guidance were not individually fully refreshed. Limited informal-source searches did not establish a new attributable rumor. This is a research-validation update, not a complete genetic-screening monitoring run.

- **2026-09-13 — Initial selective baseline:** added inherited risk, chronic-disease prediction, reproductive carrier/embryo testing, pharmacogenomics and newborn sequencing. Older studies above are baseline evidence, not newly announced news. Clinical outcomes, implementation studies and embryo simulations are explicitly separated. No comprehensive rumor sweep or exhaustive inventory of commercial tests was completed.

[September 13 scope-expansion record](../updates/2026-09-13_medical_scope_expansion.md).

### 2026-09-18 — Scheduled focused review

Original niPGT-A paper and registry, SPLENDID abstract, NAD advertising decision, newborn/PRS/embryo discovery. Original event dates, safety and limitations are retained in the September 18 update above. The complete-topic successful-check date was not advanced because the listed gaps remain. [Run record](../updates/2026-09-18_scheduled_research_update.md).